Edwards Lifesciences CORP Form 4 insider transactions

Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports disposition of shares to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported the disposal of 377 shares of common stock to cover tax obligations.

Jean-Luc M Lemercier, a CVP at Edwards Lifesciences, reported a transaction involving common stock on May 11, 2024.

Daveen Chopra, CVP of TMTT at Edwards Lifesciences, reported the disposal of 821 shares of common stock on May 11, 2024.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, executed transactions involving company stock, including the sale of 5,000 shares, under a pre-arranged 10b5-1 trading plan.

CEO Bernard J. Zovighian of Edwards Lifesciences Corp. reported the disposal of 2,854 shares of common stock to cover tax obligations.

CFO of Edwards Lifesciences, Scott B. Ullem, reports changes in beneficial ownership of company stock following a transaction on May 11, 2024.

Director Steven R. Loranger reports the acquisition of common stock and restricted stock units in Edwards Lifesciences Corp.

Nicholas J. Valeriani, a director at Edwards Lifesciences, acquired 4,818 shares of common stock through a restricted stock unit grant.

Director Ramona Sequeira reports acquisition of 3,055 restricted stock units in Edwards Lifesciences Corp.

Director Paul A. Laviolette reports the acquisition of 3,055 shares of Edwards Lifesciences Corp. common stock through a restricted stock unit grant.

Leslie Stone Heisz, a director at Edwards Lifesciences, reported the acquisition of 3,055 restricted stock units on May 8, 2024.

Director Kieran Gallahue reports the acquisition of restricted stock units and a restricted stock award from Edwards Lifesciences on May 8, 2024.

Leslie C. Davis, a director at Edwards Lifesciences, reported the acquisition of 3,055 restricted stock units on May 8, 2024.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Daveen Chopra, CVP of TMTT at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Jean-Luc Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, reports the acquisition of stock and option awards.

Larry L. Wood, Global President of TAVR & Surgical at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units, as well as the disposition of shares to cover tax obligations.

CEO Bernard J. Zovighian reports the acquisition of restricted stock units and stock options, along with a disposition of shares to cover tax obligations.

Scott Ullem, CFO of Edwards Lifesciences, reports the acquisition of stock options and restricted stock units (RSUs) and the disposition of shares to cover tax obligations.

Robert W.A. Sellers, SVP, Corporate Controller at Edwards Lifesciences, reports acquisition and disposal of common stock and stock options.

Wayne Markowitz, GM & SVP of Surgical at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units under the company's Long-Term Stock Incentive Compensation Program.

Catherine M. Szyman, CVP at Edwards Lifesciences, reports acquisition of restricted stock units and disposition of shares for tax withholding.

CEO Bernard J. Zovighian reports transactions involving Edwards Lifesciences Corp stock, including vesting of performance-based restricted stock units and acquisitions through the 401(k) plan.

CVP and CFO of Edwards Lifesciences, Scott B. Ullem, reports transactions involving common stock and performance rights.

Catherine M. Szyman, CVP at Edwards Lifesciences, reports stock transactions including the vesting of performance rights and related share disposals to cover tax obligations.

Robert W.A. Sellers, SVP, Corporate Controller of Edwards Lifesciences Corp, disposed of shares to cover tax obligations and reported changes in beneficial ownership, including acquisitions under the Employee Stock Purchase Plan.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, disposed of shares to cover tax obligations arising from equity awards.

Jean-Luc M. Lemercier, a CVP at Edwards Lifesciences, reports the vesting and subsequent disposal of shares related to performance rights.